Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Tuberous Sclerosis 3Seizures 3Sturge-Weber Syndrome 2Nausea 2Vomiting 1Parasomnias 1Pain 1Neoplasms 1Marijuana Abuse 1Dysgeusia 1Drug Resistant Epilepsy 1Cognitive Dysfunction 1Chemotherapy-Induced Peripheral Neuropathy 1Cancer Pain 1Cachexia 1Breast Neoplasms 1Behavior 1Arthralgia 1Appetitive Behavior 1Anxiety Disorders 1

Interventions

Exercise 4Walking 2Memantine 2Donepezil 2beta Carotene 1Vitamin E 1Ultraviolet Therapy 1Time 1Tai Ji 1Surveys and Questionnaires 1Sugars 1Standard of Care 1Sirolimus 1Riluzole 1Rehabilitation, Vocational 1Referral and Consultation 1Ramipril 1Radiotherapy, Intensity-Modulated 1Quality of Life 1Population Groups 1Pioglitazone 1Palliative Care 1Neuropsychological Tests 1Mindfulness-Based Stress Reduction 1Methods 1Interviews as Topic 1Ibuprofen 1Hormones 1Hematologic Tests 1Geritol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Cognitive Dysfunction × Cannabidiol × Clear all
NCT04447846 2023-05-25

Novel Cognitive Treatment Targets for Epidiolex in Sturge- Weber Syndrome

Hugo W. Moser Research Institute at Kennedy Krieger, Inc.

Phase 2 Completed
11 enrolled 25 charts

Sturge-Weber Syndrome, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡